CHINA MEDICAL UNIVERSITY HOSPITAL

The Fourth Asia-Pacific Forum on Precision Cancer Treatment highlighted advancements in breast and lung cancer care, focusing on liquid biopsy, personalized therapies, and in-depth genetic profiling. Experts discussed how these innovations enhance early detection, monitor tumor heterogeneity, and tailor treatments to improve outcomes. The forum emphasized the importance of a complete ecosystem in precision medicine, spanning detection to treatment, and the role of international collaboration in advancing cancer care.

The 2024 Taiwan Healthcare+ Expo showcased groundbreaking cancer treatments, including AI-powered diagnostics, cell and immunotherapies, precision detection, targeted therapy, radiation advancements, and novel therapeutic approaches, aiming to enhance treatment outcomes and improve patients' quality of life.

Chang Gung Memorial Hospital, Linkou validated for Stage 7 of HIMSS INFRAM and Stage 6 of DIAM, focusing on cybersecurity, infrastructure maturity, and digital imaging. The hospital plans to invest in data analytics and medical imaging management, aiming for Stage 7 DIAM and adopting AI, big data, and FHIR standards for telemedicine interoperability.

Singapore General Hospital's AI2D model, developed with DXC Technology, aims to reduce unnecessary antibiotic use and improve prescription accuracy for pneumonia cases, potentially cutting review cases by three times and identifying intervention needs more effectively. The model, trained on 8,000 SGH patients' data, demonstrated 90% accuracy in determining antibiotic necessity, suggesting 40% of prescriptions might be unnecessary. This initiative is crucial as pneumonia accounts for 20% of infections at SGH, with significant healthcare costs and risks of antimicrobial resistance.

EVER-132-002 study, compliant with Helsinki and ICH GCP guidelines, was approved by national authorities and ethics committees. It enrolled HR+HER2- metastatic or locally recurrent BC patients from China, Korea, and Taiwan, requiring prior chemotherapy and measurable disease. Patients were randomized 1:1 to receive SG or chemotherapy, with PFS as the primary endpoint. Secondary endpoints included OS, ORR, DoR, CBR, safety, and QoL. Assessments involved tumor measurements, safety evaluations, and QoL questionnaires. Statistical analysis included sample size calculation, HR estimation, and safety summaries. The study design details are available in the Nature Portfolio Reporting Summary.